α-糖苷酶抑制剂米格列醇的研究进展

Progress of α-glycosidase Inhibitor Miglitol

米格列醇是继阿卡波糖、伏格列波糖之后上市的又一α-糖苷酶抑制剂,主要用于改善糖尿病患者的餐后高血糖。越来越多的证据显示,米格列醇在控制体重、调节肠道激素分泌、改善血管内皮功能和脂质代谢等方面具有明确的疗效。胃肠道不良反应是α-糖苷酶抑制剂患者用药依从性下降的主要原因,与阿卡波糖相比,米格列醇的胃肠排气和腹部气胀的发生率更低。此外,米格列醇服用时间灵活,若餐前漏服,在进餐后的30min内服用仍能有效控制血糖升高。本文综述米格列醇的药代动力学、药理作用、联合用药、不良反应、给药方案的研究进展,以期为米格列醇在中国糖尿病患者中的临床应用提供依据。

Miglitol was another marked glucosidase inhibitor after acarbose and voglibose.Miglitol was used to improve post-prandial glucose,andgrowing evidences have shown that it may also improve body weight,incretin secretion,endothelial dysfunction and lipid metabolism in diabeticpatients.The gastrointestinal adverse effects ofα-glucosidase inhibitors were closely related to patient compliance.Compared with acarbose,miglitolhas lower incidence of flatus and abdominal bloating.If miglitol was missed at the beginning of a meal,it could be taken in30minutes after startingmeal.This review aims to summarize the clinical application of miglitol in diabetes patients from pharmacokinetics,pharmacological action,drugcombination,adverse reactions,and dosage regimen.